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ABSTRACT
Ticks are obligate haematophagous acarines that parasitise every class of vertebrate (including man) and
have a worldwide distribution. An increasing awareness of tick-borne diseases among clinicians and
scientific researchers has led to the recent description of a number of emerging tick-borne bacterial
diseases. Since the identification of Borrelia burgdorferi as the agent of Lyme disease in 1982, 11 tick-borne
human bacterial pathogens have been described in Europe. Aetiological diagnosis of tick-transmitted
diseases is often difficult and relies on specialised laboratories using very specific tools. Interpretation of
laboratory data is very important in order to establish the diagnosis. These guidelines aim to help
clinicians and microbiologists in diagnosing infection transmitted by tick bites and to provide the
scientific and medical community with a better understanding of these infectious diseases.
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INTRODUCTION
Ticks are obligate haematophagous acarines that
parasitise every class of vertebrate (including
man) and have a worldwide distribution. An
increasing awareness among clinicians and sci-
entific researchers of tick-borne diseases has led
to the recent description of a number of emer-
ging tick-borne bacterial diseases. Since the
identification of Borrelia burgdorferi as the agent
of Lyme disease in 1982, 11 tick-borne bacterial
pathogens of man have been described in Eur-
ope [1]. This review focuses on the available
diagnostic tools and provides guidelines for the
diagnosis of these diseases. These guidelines aim
to help clinicians who encounter a suspected
tick-transmitted disease, and microbiologists
who wish to standardise methods for diagnosis,
collate microbiological, clinical and epidemiolog-
ical information, and develop case definitions.
More details on the diseases, the limitations of
diagnostic tools, and the ticks themselves can be
found elsewhere [2].
RICKETTSIOSES
Agents and vectors
Tick-borne rickettsioses are caused by obligate
intracellular bacteria belonging to the spotted
fever group within the genus Rickettsia [3]. It has
been demonstrated for numerous rickettsiae that
these bacteria are maintained in ticks through
transtadial (from larva to nymph to adult) and
transovarial (from one generation to another
through ovaries) transmission. Thus, ticks may
act as reservoirs for these bacteria, and the
geography of tick-borne rickettsioses is deter-
mined by the distribution of ticks. The role of
vertebrates as reservoirs in maintaining zoonotic
foci has yet to be determined. When transmitted
to man, the pathogenic rickettsiae multiply in
endothelial cells and cause a vasculitis, which is
responsible for the clinical and laboratory abnor-
malities that occur in rickettsioses [4].
Until recently, Mediterranean spotted fever
(MSF) was considered to be the only rickettsiosis
prevalent in Europe. This disease, also known as
‘boutonneuse’ fever, is caused by Rickettsia conorii
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and is transmitted by the brown dog tick Rhipi-
cephalus sanguineus. However, five new autoch-
thonous tick-borne rickettsioses have been
described in Europe during the last decade. These
new rickettsioses include infections caused by
‘Rickettsia mongolotimonae’ (southern France) [5,6],
Rickettsia slovaca (throughout Europe) [7,8], Rick-
ettsia helvetica (throughout Europe) [9], R. conorii
Israel strain (Sicily and Portugal) [10] and
R. conorii Astrakhan strain (Astrakhan, Kosovo)
[11]. In addition, African tick-bite fever (ATBF)
caused by Rickettsia africae is now recognised
frequently as a travel-associated illness in travel-
lers returning to Europe [12,13]. A new spotted
fever caused by Rickettsia parkerii was reported in
the USA in 2004 [14].
Each Rickettsia sp. has one or several tick
vectors, and it is the geographical distribution,
seasonal activity, host-seeking behaviour or ten-
dency of these arthropods to bite humans that
underlies the epidemiology of the disease [2]. In
addition to the organisms described above, some
other rickettsiae that have yet to be implicated in
human disease have been isolated from ticks [4].
Clinical and standard laboratory features
Typically, the clinical symptoms of tick-borne
rickettsioses begin 6–10 days after a tick bite, and
include fever, headache, muscle pain, rash
(Fig. 1), local lymphadenopathy and a character-
istic inoculation eschare (‘tache noire’) at the site
of the tick bite (Figs 1 and 2) [4]. However, these
major clinical signs vary with the rickettsial
species involved (Table 1). Non-specific haemato-
logical and biochemical findings include thromb-
ocytopenia, leukocyte count abnormalities and
elevated hepatic enzyme levels [15,16]. Further
studies of atypical cases have also led to the
description of new clinical syndromes caused by
organisms previously considered as ‘rickettsiae of
unknown pathogenicity’, including R. slovaca and
R. helvetica [8,9,17].
Collection and preservation of samples
Before antimicrobial therapy, a minimum of 5 mL
of blood should be collected for culture in either
heparin- or citrate-containing tubes (leukocyte cell
buffy coat), or EDTA tubes for molecular diagno-
sis. EDTA anticoagulant should be avoided for
culture, as it is harmful to the cell monolayers used
for recovery of rickettsiae. Heparinised blood can
also be used for immunocytological detection of
rickettsiae in circulating endothelial cells [18].
When culture or molecular diagnosis (based on
PCR) is delayed for > 24 h, samples (plasma, buffy
coat or whole blood) should be frozen at ) 70C or
in liquid nitrogen for isolation procedures, or at
) 20C for molecular diagnosis.
For serological diagnosis, 10 mL of blood
should be collected early in the course of the
disease, and a second sample should be obtained
2 weeks later. If a four-fold rise in antibody titre is
not observed, collection of a third sample after
4–6 weeks should be considered. Sera can be
preserved at or below ) 20C for several months
without degradation of the antibodies. An alter-
native, inexpensive and convenient method for
collecting, storing and transporting blood samples
suitable for serological testing is to collect a few
Fig. 1. Maculopapular rash of Mediterranean spotted
fever. Note the inoculation eschar surrounded by a
purpuric lesion.
Fig. 2.19 Typical eschar (‘taˆche noire’) of tick-transmitted
rickettioses. A scalp location of the eschar indicates tick-
borne lymphadenopathy caused by Rickettsia slovaca.
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drops of blood on to blotting paper [19]. Skin
biopsy specimens, collected before antimicrobial
therapy (preferably from the site of tick attach-
ment), are particularly valuable clinical samples
that can be used for culture, immunohistochem-
istry and PCR. If processing of biopsy material is
delayed, the sample should be preserved frozen
at ) 70C for culture and PCR, or in formalin for
immunohistochemistry.
Tools available for diagnosis
Serology
Serological tests are the easiest methods for the
diagnosis of tick-borne rickettsioses. The various
techniques available have been reviewed else-
where, but microimmunofluorescence (MIF) is
accepted widely as the reference method [20]. MIF
should be used to detect IgM and IgG in acute
and convalescent sera. Currently, at the Unite´ des
Rickettsies in Marseilles, IgG titres ‡ 128 and ⁄ or
IgM titres ‡ 64 are considered indicative of infec-
tion by R. conorii in suspected cases of MSF,
whereas IgG titres ‡ 64 and ⁄ or IgM titres ‡ 32 are
considered indicative of infection by other
Rickettsia spp. in other rickettsioses. IgM and
IgG are usually both detected 7–15 days after
disease onset. However, the IgG and the IgM
responses to R. africae are delayed in ATBF
patients, with median seroconversion times of 28
and 25 days after the onset of symptoms for IgG
and IgM, respectively [21]. Doxycycline treatment
within 7 days of the onset of disease has been
shown to prevent the development of antibodies
to R. africae [21]. Thus, the sensitivity of MIF is
low in the early stages of ATBF, and it is
recommended that sera collected 4 weeks after
the onset of illness should be used for the
definitive serological diagnosis of R. africae infec-
tion in patients suspected of having this syn-
drome [21]. Serological responses also appear to
be slower to develop in patients infected with
R. slovaca, but this aspect requires further inves-
tigation, as only a small number of patients have
been studied.
The interpretation of serological data can be
confounded by the cross-reactivity that occurs
among the spotted fever group rickettsiae. Tests
for a single antigen do not allow a definitive
conclusion regarding the causative agent [22],
Table 1. Geographical distribution and symptoms of the tick-borne rickettsioses in Europe
Diseases Rickettsia Vector(s) Distribution
Epidemiological
features
Clinical features
Fever
Diffuse
rash Eschar
Enlarged
local
nodes
Fatality
rate
without
treatment
Mediterranean
spotted
fever
R. conorii Rhipicephalus
sanguineus
Mediterranean
areaa
Urban (2 ⁄ 3)
Rural (1 ⁄ 3)
Late spring
and summer
100% 97%
(10%
purpuric)
72% Rare 1–2.5%
TIBOLA R. slovaca Dermacentor
marginatus
D. reticulatus
From
western
Europe to
central
Asia
Spring,
autumn and
winter
24% Low
(8%)
Yes
(scalp)
Cervical
(44%
painful)
Israeli
spotted
fever
R. conorii
Israel
Rh. sanguineusb Portugal,
Sicily
Yes 100% No No < 1%
Astrakhan
fever
R. conorii
Astrakhan
Rh. pumillio
Rh. sanguineus
Astrakhan,
Kosovo
Yes 100% 23% No
Unnamed R. mongolotimonae Unknown Southern
Francec
Yes Yes Yes
(may be
multiple)
No
Unnamed R. helvetica Ixodes ricinus From
northwestern
Europe to
central Asia
Yes ? ? ? ?
African
tick
bite
fever
R. africae Amblyomma
hebraeum
A. variegatum
Sub-Saharan
Africa
West Indiesd
Imported
disease
Safari
Grouped
cases or
epidemic
81–92% 42–50%
(50%
vesicular)
53–98%
(55%
multiple)
49–57%
TIBOLA, Tick-borne lymphadenopathy.
aCases may occur in northern countries, as brown dog ticks survive easily in homes and the human environment.
bR. conorii Israel has not yet been detected in ticks in Portugal, and the vector in this country is not yet known.
cFew cases reported.
dImported from sub-Saharan Africa and the West Indies.
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although tests for several antigens on the same
slide may allow the causative agent to be identi-
fied from its comparatively higher antibody level
[12,23]. Western blotting will yield false-positive
results because of cross-reacting antibodies,
which are directed mainly against lipopolysac-
charide, but is useful in detecting antibodies early
in the course of MSF. Western blotting, partic-
ularly in conjunction with sera that have been
cross-absorbed, can also be used to identify the
infecting rickettsial species, but the technique is
only suited to reference laboratories [24] (Fig. 3).
Table 2 shows a comparison of data regarding the
diagnostic value of the above-mentioned serolog-
ical tests. Table 3 sets out the diagnostic criteria
used for interpreting the results of the standard
MIF procedure. Immunodetection methods may
also be used to identify rickettsiae in biopsy
specimens and arthropods.
Cultivation
Isolation of rickettsiae is of great importance, as
the ultimate diagnostic goal is recovery of the
bacterial agent from a tick or a patient. Spotted
fever group rickettsiae are strictly intracellular,
short Gram-negative bacilli that retain basic fuch-
sin when stained by the method of Gimenez [25].
Rickettsiae can be grown in vitro in tissue cell
cultures, but isolation attempts must be per-
formed only in Biosafety Level 3 laboratories.
Rickettsiae are isolated most commonly from
blood (decanted plasma, collected on heparin or
citrate anticoagulant), skin biopsy specimens
(with the inoculation eschar being the best speci-
men to use) or ticks. The centrifugation shell vial
technique, first developed for cytomegalovirus
culture and early antigen detection, has been
adapted for the isolation of R. conorii; in most
cases, cultured microorganisms are detectable
48–72 h post-inoculation [26]. In a study based
Absorbed RC
RC-RARC-RA RC-RA
Absorbed RANot absorbed208
131
96
43.9
35.4
17.8
8.3
MWM
Fig. 3. Western blotting and cross-absorption study to
differentiate between Rickettsia conorii (RC) and Rickettsia
africae (RA) infection. Once absorbed with RA, the anti-
bodies that remain are those directed against RC; all
antibodies disappeared following absorption with RC,
indicating that antibodies contained in the sera were
directed specifically against R. conorii. MWM, molecular
size marker.
Table 2. Value of serological tests in the diagnosis of
rickettsial diseases
Disease Test Se Sp PPV NPV Ref.
Rocky Mountain
spotted fevera
IFA 100 – – – [172]
Rocky Mountain
spotted feverb
IFA – – – – [173]
‡ 1 ⁄ 64 84.6 100
‡ 1 ⁄ 32 97.4 99.8
Mediterranean
spotted feverc
IFA ‡ 1 ⁄ 40 – – – – [174]
Sampling day 5–9 46
Sampling day 20–29 90
Sampling after day 29 100
African tick
bite feverd
– – – – – [12]
IFA 26 100 100 –
CA 83 100 100 –
WB 53 100 100 –
IF + CA + WB 56
CA, Cross-absorption; IFA, immunofluorescence assay; WB, Western blot; Se,
sensitivity; Sp, specificity; PPV, positive predictive value; NPV, negative predictive
value.
aSixty paired sera, including specimens with stationary titres (5%) and four-fold
rising titres (95%).
bStudy of 417 sera from 178 patients who very probably did not have rickettsial
infections, and 88 sera from 41 patients who very probably had Rocky Mountain
spotted fever.
cOne hundred and eighty-four sera tested.
dFour hundred and fourteen patients tested for R. africae, with 39 confirmed by PCR
or culture, and 81 considered positive on the basis of IFA + WB + CA.
Table 3. Standard procedure used at the Unite´ des Rick-
ettsies for the diagnosis of rickettsioses when cross-reac-
tions are noted between several rickettsial antigens in the
microimmunofluorescence test [20]
1. A rickettsial antigen is considered to be implicated in the infection when titres
of IgG and ⁄ or IgM antibody against this antigen are at least two serial
dilutions higher than titres of IgG and ⁄ or IgM antibody against other
rickettsial antigens
2. When differences in titres between several antigens are < 2 dilutions, Western
blot assays are performed. A rickettsial antigen is then considered to be
implicated in the infection when acute sera show an exclusive
reactivity with the specific proteins of this antigen
3. When Western blots are non-contributive, cross-absorption studies are
performed when IgG ⁄ IgM titres are ‡ 128 ⁄ 32. Specific diagnostic criteria after
cross-absorption studies are: (1) immunofluorescence serology
positive for a single antigen; or (2) Western blot assay showing exclusive
reactivity with the specific proteins of an antigen
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on specimens collected from 157 suspected MSF
cases before the prescription of antimicrobial
agents, R. conorii was isolated from 59% of
patients with a concurrent MIF titre of £ 1 ⁄ 32
[20]. In 34 of these patients, R. conoriiwas detected
as soon as day 3 after the tick bite, i.e., before
seroconversion. However, when samples were
not inoculated on the day of sampling, but held at
room temperature or at 4C overnight before
inoculation, no culture was positive. When the
shell vial technique is used, the small surface area
(1–2 cm) of the coverslips on which cell mono-
layers are established enhances the ratio of rick-
ettsiae to cells, thereby allowing better recovery.
Vero or L929 cells have been shown to be more
suitable than HEL or MRC5 cells for the isolation
of rickettsiae. Nevertheless, the use of HEL or
MRC5 cells is more convenient, as once a mono-
layer is established, contact inhibition prevents
further division, and the cells can then be used for
prolonged incubation. Centrifugation of the shell
vial following the introduction of material sus-
pected of containing rickettsiae is critical for the
sensitivity of the technique, because it enhances
rickettsial attachment and penetration of the cell
monolayer. Detection of rickettsiae within the
cells can be achieved by microscopic examination
after Gimenez staining, immunodetection or PCR.
If immunofluorescence is negative after 20 days,
the culture is considered negative. If immuno-
fluorescence is positive, parallel shell vials are
inoculated on to confluent monolayers of HEL
cells in culture flasks, in an attempt to obtain
isolates of Rickettsia spp.
Molecular methods
Molecular methods based on PCR have enabled
the development of sensitive, specific and rapid
tools for both the detection and identification of
rickettsiae in blood, skin biopsy specimens (the
‘tache noire’ being the most useful specimen)
and even ticks. Primer sets targeting various
rickettsial genes have been described (Table 4)
and can be used in any laboratory with suitable
facilities.
Case definition
A flow chart outlining laboratory methods for the
diagnosis of rickettsioses is presented in Fig. 4.
Case definitions and diagnostic scores have been
established for ATBF (Table 5) and MSF (Table 6),
but not for other less established rickettsial
diseases.
ANAPLASMOSIS (EHRLICHIOSES)
The agent and its vector
Human (granulocytic ehrlichiosis) anaplasmosis
is an acute infectious disease caused by Anaplasma
phagocytophilum (formerly human granulocytic
ehrlichia, Ehrlichia phagocytophila, Ehrlichia equi)
and was first characterised in the northern USA in
1994 [27]. This bacterium belongs to the order
Rickettsiales within the a-Proteobacteria [28].
A. phagocytophilum is an obligate intracellular
pathogen that parasitises the granulocytes of
man and animals. Although this agent has been
associated only recently with disease in man, its
role in the aetiology of tick-borne fever in Euro-
pean livestock has been recognised since the
1930s [29]. The bacterium has been detected by
PCR in Ixodes ticks from most European countries,
including France [30], Slovenia [31], Switzerland
[32,33], The Netherlands [34], northern Italy [35],
Bulgaria [36], southern Norway [37], the Baltic
region of Russia [38], southern Germany [39,40],
the UK [41] and Spain [42]. The prevalence of
A. phagocytophilum in ticks ranged from 2% to
45% [30,34].
The first European case of human anaplasmosis
was reported in 1995 in Slovenia [43]. Although
serological evidence of the disease has been
reported frequently in most European countries
[42,44–53], few acute cases have been confirmed
by observation of a four-fold increase in specific
antibodies, the presence of morulae in circulating
granulocytes, or PCR-based detection of the
organism in the blood. To our knowledge, only
22 confirmed cases have been reported to date,
comprising one case from The Netherlands [54],
two from Sweden [55,56], 13 from Slovenia
[43,57–60], one from Spain [61], one from Austria
[62], three from Poland [63] and one from France
[64].
Clinical and laboratory characteristics
Human anaplasmosis is an acute tick-borne infec-
tion. Most patients recall a tick bite before the
onset of their illness. The incubation period
ranges from 5 to 21 (median, 11) days. Most cases
of human granulocytic ehrlichia occur between
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April and October, peaking in July. Patients
present with an acute non-specific febrile illness
characterised by high-grade fever (> 38.5C),
chills, severe headache and generalised myalgias
and ⁄ or arthralgias. Significantly more infections
have been reported in males than in females, with
an age range of 11–73 years. The duration of fever
is 2–11 days (median, 10 days). Less common
symptoms include nausea, abdominal pain, diar-
rhoea and cough. Skin rash and confusion are
very infrequent findings. The results of physical
examination are often unremarkable. Interest-
ingly, several cases of human anaplasmosis have
presented as atypical pneumonitis [60,63,64].
Approximately one-half of patients with acute
anaplasmosis require hospitalisation. Complica-
tions are unusual, and opportunistic infections
have not yet been described in European patients.
Clinical features and laboratory findings reported
in patients from Europe are similar to those
reported from the USA, although the disease
appears to be generally milder and to resolve
sooner, even in the absence of specific antimicro-
bial therapy [57,59,65,66]. No fatal infections or
long-term sequelae have been reported. No chro-
nic forms of the illness have yet been documented
in Europe, although A. phagocytophilum DNA has
been demonstrated in the convalescent blood of
Table 4. DNA targets that have
been exploited for detection of rick-
ettsia in samples of infected patients
Gene used and species Forward and reverse primers Method Sample Ref.
Citrate synthase (gltA) RpCS.877p: GGGGACCTGCTCACGGCGG Regular PCR Skin [175]
All species RpCS.1258n: ATTGCAAAAAGTACAGTGAACA
Outer-membrane protein A
(ompA)
Rr190.70p: ATGGCGAATATTTCTCCAAAA
Rr190.602n: AGTGCAGCATTCGCTCCCCCT
Regular PCR Skin [175]
All species except
R. helvetica, R. australis,
R. bellii, R. canadensis,
Rr190.70p: ATGGCGAATATTTCTCCAAAA
Rr190.701n: GTTCCGTTAATGGCAGCATCT
Regular PCR
ompA AF1F: CACTCGGTGTTGCTGCA ‘Suicide PCR’a Serum [12]
AF1R: ATTAGTGCAGCATTCGCTC
AF2F: GCTGCAGGAGCATTTAGTG
AF2R: TATCGGCAGGAGCATCAA
AF3F: GGTGGTGGTAACGTAATC ‘Suicide PCR’a
AF3R: CGTCAGTTATTGTAACGGC
AF4F: GGAACAGTTGCAGAAATCAA
AF4R: CTGCTACATTACTCCCAATA
Outer-membrane protein B
(ompB)
BG1-21: GGCAATTAATATCGCTGACGG
BG2-20: GCATCTGCACTAGCACTTTC
Regular PCR Skin [175]
All species except
R. helvetica, R. bellii,
R. massiliae
aNote that primers used for this nested PCR are used only once in a particular laboratory, with no positive control.
Other pairs of primers can be designed each time that a new screening is performed; these can be selected to target
other rickettsial genes.
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Fig. 4. Collection of samples and
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one patient on the 22nd day after the onset of
illness and 16 days after defervescence [59].
Haematological and biochemical tests can be
helpful for diagnosis, but the findings are non-
specific. The most common laboratory abnormal-
ities are thrombocytopenia (90%) and leukopenia
(70%), usually accompanied by abnormal liver
function, manifesting as mild increases in serum
concentrations of aspartate aminotransferase,
alanine aminotransferase and, most frequently,
lactate dehydrogenase. An elevated concentration
of C-reactive protein has been found in almost all
patients with acute human granulocytic ehrlichia.
Other less common laboratory findings are
anaemia, and elevated serum creatinine and
blood urea nitrogen levels. In general, all labor-
atory abnormalities found in European patients
resolve within 14 days of initial presentation.
Acute human anaplasmosis has a clinical and
laboratory presentation remarkably similar to the
initial phase of infection by tick-borne encephal-
itis virus, which is an endemic disease in nor-
thern, central and eastern Europe. Comparison of
clinical signs, symptoms and laboratory findings
in patients with these two syndromes has, how-
ever, revealed several significant differences [67].
The possibility of human anaplasmosis should be
suspected each time a patient in an endemic
region presents with an undifferentiated febrile
illness occurring after a tick bite or tick exposure.
Collection and preservation of samples
For isolation of the agent, blood should be
collected during the acute phase of the disease
when circulating infected neutrophils are at their
highest concentration [68]. The blood should be
collected, preferably on EDTA, and kept either at
room temperature [69] for not more than 48 h or
frozen at ) 20C before inoculation [70]. Sam-
ples of citrate-anticoagulated blood containing
A. phagocytophilum were shown to be infective for
10 days if stored at room temperature, or for
13 days if stored at 4C [68]. Although heparin-
anticoagulated blood has been used successfully
to infect animals, routine use of anticoagulant
should be avoided because of its ability to
compromise PCR-based detection methods.
Transportation of clinical material to the laborat-
ory should be performed as quickly as possible at
room temperature, or at ) 20C if transport times
are expected to be > 48 h.
For serology, at least two sera should be
collected, one during the acute phase and one
after 15–21 days during the convalescent phase.
Sera should be kept at 4C or frozen at ) 20C.
Information on the duration and kinetics of the
antibody response following acute anaplasmosis
is limited in Europe, and is based entirely on a
report from Slovenia. Significant antibody titres
were detectable in 40% of patients for 2 years
after the initial presentation [65].
Diagnosis of infection by observation of infec-
ted phagocytes in blood smears is best achieved if
smears are prepared immediately after blood
collection. Smears should be air-dried and pre-
served at room temperature.
Table 5. Diagnostic criteria for African tick bite fever
(ATBF); a patient is considered to have ATBF when criteria
A, B or C are met
A. Direct evidence of R. africae infection by culture and ⁄ or PCR
or
B. Clinical and epidemiological features highly suggestive of ATBF, such as
multiple inoculation eschars and ⁄ or regional lymphadenitis and ⁄ or a vesicular
rash and ⁄ or similar symptoms among other members of the same
group of travellers coming back from an endemic area (sub-Saharan Africa or
French West Indies)
and
Positive serology against spotted fever group rickettsiae
or
C. Clinical and epidemiological features consistent with a spotted fever group
rickettsiosis such as fever and ⁄ or any cutaneous rash and ⁄ or single inoculation
eschar after travel to sub-Saharan Africa or French West Indies
and
Serology specific for a recent R. africae infection (seroconversion or presence of
IgM ‡ 1:32), with antibodies to R. africae greater than those to R. conorii by
at least two dilutions, and ⁄ or a Western blot or cross-absorption showing
antibodies specific for R. africae
Table 6. Diagnostic criteria for Mediterranean spotted
fever caused by Rickettsia conorii
Criteria Scorea
Epidemiological criteria
Stay in endemic area 2
Occurrence in May–October 2
Contact (certain or possible) with dog ticks 2
Clinical criteria
Fever > 39C 5
Eschar 5
Maculopapular or purpuric rash 5
Two of the above criteria 3
All three of the above criteria 5
Non-specific laboratory findings
Platelets < 150 G ⁄L 1
SGOT or SGPT >50 U ⁄L 1
Bacteriological criteria
Blood culture positive for Rickettsia conorii 25
Detection of Rickettsia conorii in a skin biopsy 25
Serological criteria
Single serum and IgG > 1 ⁄ 128 5
Single serum and IgG > 1 ⁄ 128 and IgM > 1 ⁄ 64 10
Four-fold increase in two sera obtained within a 2-week interval 20
SGOT, serum glutamate–oxaloacetate transaminase; SGPT, serum glutamate–
pyruvate transaminase.
aA positive diagnosis is made when the overall score is ‡ 25.
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Diagnostic tools
Serology
Detection of circulating antibodies is assessed by
indirect immunofluorescence antibody testing.
The antigens used in these assays vary (Table 7).
A. phagocytophilum antigen, grown intracellularly,
is usually coated on to glass slides, fixed with
cold acetone or alcohol, and preserved either at
) 20C or in light-protected paper. Alternatively,
cell-free antigen may be prepared by purification
of infected cell culture, and preserved either
frozen or at 4C in solution with sodium azide
1% w ⁄v in phosphate-buffered saline. In the
latter case, the slide can be prepared on the day
of use by the addition of antigen with a pen-nib,
followed by fixation in either cold acetone or
alcohol [71].
Cultivation
Isolation of A. phagocytophilum should only be
attempted in a Biohazard Level 3 laboratory. The
promyelocytic HL-60 leukaemia cell line (ATCC
CCL240) is the most widely used cell line for
growing A. phagocytophilum [69]. These cells are
maintained in antibiotic-free RPMI-1640 medium,
supplemented with 2 mM glutamine and fetal
bovine serum 20% v ⁄ v, and incubated at 37C in
CO2 5%. Fresh blood (100 lL) [69], or 0.5 mL of
the leukocyte fraction of previously frozen
() 20C) EDTA–blood [70], can be inoculated into
a 25-cm2 flask containing HL-60 cells at a density
of 2 · 105 cells ⁄mL. Infection can be assessed by
Giemsa staining of CytoSpin cells. Infection is
usually detectable as observable morulae at days
3–7 post-inoculation [70].
Molecular detection
PCR-based methods are not yet standardised
and may yield discrepant results. Detection of
A. phagocytophilum DNA has been achieved from
blood and from acute-phase sera (before day 21)
of infected patients [72]. Few techniques have
been evaluated properly, but several PCR targets
have been described (Table 8). In a study invol-
ving cases of human anaplasmosis where infec-
tion had been confirmed by seroconversion, PCR
targeting a fragment of the epank gene detected
DNA in all patients, while PCR targeting a 16S
rRNA gene fragment failed to do so [73]. The
detection limits of 13 published PCR assays have
been assessed, and those targeting fragments of
the msp2 homologues or the 16S rRNA gene were
found to be the most sensitive [74]. Discrepancies
in PCR sensitivity might be related to the length
of the amplicon and the primer used. Whichever
DNA target is chosen, sequencing of PCR prod-
ucts is mandatory to confirm their identity. The
use of broader-range, genus-specific PCRs is not
recommended, as knowledge of the true diversity
of A. phagocytophilum or the Anaplasma genus is, as
yet, very limited [34,75]. However, until issues
concerning sensitivity and specificity of the var-
ious assays have been better addressed, the best-
Table 7. Serological tests available
for testing Anaplasma phagocytophi-
lum antibody in man
Laboratory IFA
(Se/Sp) IgG,
(Se/Sp) IgM Antigen source
Commercial
test Ref.
Unite´ des
Rickettsies, Francea
IgG, IgM (80 ⁄ 92.7), (40 ⁄ 94.1) HGE
Webster strain
(human isolate)
No [71]
Kalmar County Hospital,
Swedenb
IgG Not evaluated SMA 308
(Swedish isolate)
No [176]
Institute for Microbiology
and Immunology,
Sloveniac
IgG Not evaluated USG3
(tick isolate)
No [65]
University of Zurich,
Switzerlandd
IgG Not evaluated A. phagocytophilum
(Swiss strain)
No [47]
MRL Diagnostics,
USAe
IgG, IgM 86.6 ⁄ 92.7, 33 ⁄ 98 HGE 1
(human isolate)
Yes [46]
[71]
Pettenkofer-Institute,
Germanyf
IgG, IgM Not evaluated HGE
(human isolate)
No [71]
IFA, immunofluorescence assay; Se, sensitivity; Sp, specificity.
aUnite´ des Rickettsies, Faculte´ de Me´decine, 27 bd J Moulin, 13385 Marseille cedex 5, France. E-mail:
didier.raoult@medecine.univ-mrs.fr.
bDepartment of Clinical Microbiology, Research Center for Zoonotic Ecology and Epidemiology, Kalmar County
Hospital, 391 85 Kalmar, Sweden. E-mail: anneli.bjoersdorff@ltkalmar.se.
cInstitute for Microbiology and Immunology, Medical Faculty, Ljubljana, Slovenia. E-mail: tatjana.avsic@mf.uni-
lj.si.
dDepartment of Veterinary Internal Medicine, University of Zurich, Winterthurerstrasse 260, CH-8057 Zurich,
Switzerland
eMRL Diagnostics, Cypress, CA, USA.
fMax von Pettenkofer-Institute, Consiliary Laboratory for Ehrlichiae, University of Munich, Pettenkofer-Strasse 9a,
D80336 Mu¨nchen, Germany. E-mail: Bettina.Wilske@mvp-bak.med.uni-muenchen.de.
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evaluated methods are recommended for clinical
application.
Case definition
There have been too few reported cases of acute
human ehrlichioses to allow the precise definition
of the clinical spectrum of human anaplasmosis in
Europe. The case definition summarised in Table 9
is based on the epidemiological, clinical and labor-
atory characteristics of reported cases in Europe, as
well as the diagnostic tools described above.
LYME BORRELIOSIS
The agent and its vector
Lyme disease is a multisystem disease caused by
bacteria termed Borrelia burgdorferi sensu lato (sl).
B. burgdorferi sl is a spirochaete, helically shaped,
motile, 20–30 lm in length and 0.2–0.3 lm in
width [76]. Within B. burgdorferi sl, three human
pathogens are recognised, namely B. burgdorferi
sensu stricto (ss), Borrelia afzelii and Borrelia garinii
[77,78]. Only B. burgdorferi ss is encountered in
North America, while all three species exist in
Europe. Another species, Borrelia lonestari [79], has
been reported to cause human disease [80], and
other species have been described recently, inclu-
ding Borrelia japonica [81], Borrelia andersonii [82],
Borrelia lusitaniae [83], Borrelia miyamotoi [84],
Borellia turdae [85], Borrelia tanukii [85] and Borrelia
valaisiana [86]. It has been suggested, but not yet
demonstrated, that the last of these may be a
human pathogen.
Ixodes ticks transmit all species belonging to
B. burgdorferi sl. Tick larvae and nymphs feed
primarily on small rodents and birds, whereas
adult ticks feed on a variety of mammals (deer,
domestic and wild carnivores, and larger domes-
tic animals). The feeding time of Ixodes ticks (in
Europe, primarily I. ricinus) is long (several days
to > 1 week); during this period, the ticks are
dispersed on a scale that depends on the range of
their hosts. Birds, particularly migratory sea
birds, can transport ticks (Ixodes uriae) over very
long distances, and thus distribute borreliae
(especially B. garinii) worldwide [87]. There is an
association between certain B. burgdorferi sl spp.
and specific vertebrate hosts, e.g., between
B. afzelii and small rodents, and between B. garinii,
B. valaisiana and birds [88].
Clinical and laboratory characteristics
B. burgdorferi ss, B. afzelii and B. garinii are
associated with different clinical manifestations
Table 8. DNA targets that have been used for the detection of Anaplasma phagocytophilum in samples from infected patients
Gene used Forward and reverse primers Method Sample Sensitivity/specificity Ref.
16S rRNA GE9f, 5¢-AACGGATTATTCTTTATAGCTTGCT-3¢ Regular PCR Blood 86% ⁄ 100% [43,72,177]
GE10r, 5¢-GGAGATTAGATCCTTCTTAACGGAA-3¢
16S rRNA EC9, 5¢-AAGGATCCTACCTTGTTACGACTT-3¢ Nested Serum Not evaluated [178,179]
EC12, 5¢-AATCTAGATTAGATACCCT(A ⁄T ⁄G)GTAGTCC-3¢
Ge9f, 5¢-AACGGATTATTCTTTATAGCTTGCT-3¢
Ge10r, 5¢-GGAGATTAGATCCTTCTTAACGGAA-3¢
Epank1 LA6, 5¢-GAGAGATGCTTATGGTAAGAC-3¢ Regular PCR Blood 95% ⁄ 100% [73]
LA1, 5¢-CGTTCAGCCATCATTGTGAC-3¢
HGE 44 Not published Regular PCR Blood Not evaluated [54]
P44 (msp2)
paralog sequence
P44f1-5¢-TTGATCTTGAGATTGGTTACG-3¢ Nested suicide Serum Not evaluated [64,180]
P44r1-5¢-GGCAGATCATCATAAACRCC-3¢
P44f2-5¢-CAAGGGTATTAGAGATAGT-3¢
P44r2-5¢-AAACTGAACAATATCCTTAC-3¢
GroESL HS1, 5¢-TGGGCTGGTA(A ⁄C)TGAAAT-3¢ Nested Blood Not evaluated [57,181]
HS6, 5¢-CCICCIGGIACIA(C ⁄T)ACCTTC-3¢
HS43, 5¢-AT(A ⁄T)GC(A ⁄T)AA(G ⁄A)GAAGCATAGTC-5¢
HS45, 5¢-ACTTCACG(C ⁄T)(C ⁄T)TCATAGAC-3¢
Table 9. Proposed case definition for human anaplasmosis
Confirmed human anaplasmosis
1. Febrile illness with a history of a tick bite or tick exposure
and
2. Demonstration of Anaplasma phagocytophilum infection by seroconversion or
‡ 4-fold change in antibody titrea
or
3. Positive PCR result with subsequent sequencing of the amplicons
demonstrating Anaplasma-specific DNA in blood
or
4. Isolation of A. phagocytophilum in blood culture
Probable human anaplasmosis
1. Febrile illness with a history of a tick bite or tick exposure
and
2. Presence of stable titre of A. phagocytophilum antibodies in acute and
convalescent sera if titre > 4-fold above the cut-off valuea
or
3. Positive PCR result without sequence confirmationb
or
4. Presence of intracytoplasmic morulae in a blood smear
aBy immunofluorescence assay, with use of either intracellular or purified
antigen in a reference laboratory or the MRL Diagnostics (Cypress, CA, USA) kit.
bWith use of the species-specific primers listed in Table 8.
1116 Clinical Microbiology and Infection, Volume 10 Number 12, December 2004
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 1108–1132
of Lyme disease [89–92]. Three stages are usually
described: stage I, early ⁄ localised infection; stage
II, early ⁄disseminated infection; and stage III,
late ⁄persistent infection. The initial clinical pres-
entation (stage I) involves skin lesions—erythema
migrans (EM), the pathognomonic sign associated
with all three species—that occur early at the site
of the tick bite in the form of a gradually
extending erythematous lesion (Fig. 5). Other
secondary ring-shaped lesions develop in certain
cases. A rare, but typical, skin lesion is borrelia
lymphocytoma, a bluish-red tumour-like skin
infiltrate, most often localised at the ear lobe, the
nipples and areola mammae. Joint lesions occur
between a few weeks and 2 months after disease
onset in the form of polyarthralgia or true
arthritis, usually in the knee (80% of untreated
patients in the USA) (stage II). It has been
proposed that Lyme arthritis is associated more
frequently with B. burgdorferi ss infections, but
this hypothesis remains controversial [92].
Neurological manifestations (associated most
frequently with B. garinii) show considerable
variety, ranging from isolated meningitis to
encephalopathy, and include meningoradiculitis
and lesions of pairs of cranial nerves (usually
resulting in facial paralysis such as Bell’s palsy).
In general, these manifestations are of late onset,
but they may also be observed during the EM
period. Neurological manifestations are reported
more frequently in Europe. In the weeks follow-
ing the onset of disease, cardiac involvement is
observed in 5% of cases, usually with electrocar-
diographic signs of myocarditis (conduction dis-
order and, sometimes, atrioventricular block).
Acrodermatitis chronica atrophicans (ACA) is
associated with B. afzelii, and is generally
observed (stage III) several years after EM. ACA
begins with a characteristic bluish-red discolor-
ation, often with a doughy infiltration, and then
progresses to atrophy of the skin, and is some-
times complicated by sclerodermic changes.
Collection and preservation of samples
When culture of borreliae is being attempted,
collection and preparation of specimens under
aseptic conditions is essential. Body fluids should
be transported without any additives, and biopsy
specimens should be placed in a small quantity of
sterile saline or suitable culture medium [92].
Samples should reach the laboratory as quickly as
possible after collection (within 2–4 h). Before
specimens are collected and transported, the
laboratory should be contacted so that details
related to methodology can be agreed upon. If
postal transport is unavoidable, overnight deliv-
ery is recommended.
Specimens used for diagnosis of Lyme
borreliosis
Serum is among the samples of choice (Table 10),
as serology is used widely for the diagnosis of
Fig. 5. The pathognomonic sign associated with Lyme
borelliosis, which occurs early at the site of the tick bite in
the form of a gradually extending erythematous lesion
termed erythema migrans.
Table 10. Specimen types used for the diagnosis of Lyme
disease [92]
Clinical manifestation
Specimens for
Direct pathogen
detection
Antibody
detection
Stage I (early ⁄ localised)
(days to weeks after tick bite)
Erythema migrans Skin biopsy specimen Serum
Stage II (early ⁄disseminated)
(weeks to months after tick bite)
Multiple erythemata Skin biopsy specimen Serum
Borrelial lymphocytoma Skin biopsy specimen Serum
Lyme carditis Endomyocardial biopsy Serum
Neuroborreliosis CSF Paired
serum ⁄CSFa
Ophthalmoborreliosis Serum
Stage III (late ⁄persistent)
(months to years after tick bite)
Arthritis Synovial fluid,
synovial biopsy
Serum
Acrodermatitis chronica
atrophicans
Skin biopsy specimen Serum
Chronic neuroborreliosis CSF Paired
serum ⁄CSFa
aPaired serum and CSF specimens are obtained on the same day for CSF
antibody ⁄ serum antibody index determination.
CSF, cerebrospinal fluid.
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Lyme disease. In suspected cases of neuroborrel-
iosis, cerebrospinal fluid (CSF) and a concurrent
serum sample should be obtained for determin-
ation of cell counts ⁄differentials, protein content
and intrathecal immunoglobulin synthesis. Labor-
atory confirmation of neuroborreliosis is achieved
most readily by demonstration of borrelia-speci-
fic, intrathecal antibody production. CSF can also
be used for culture or PCR; however, detection
rates with these approaches are only 20% [93].
PCR investigation of synovial fluid or, preferably,
a synovial biopsy specimen, is recommended for
patients in whom Lyme arthritis is suspected
[94,95]. The high protein permeability of the
synovium means that synovial fluid and serum
display roughly equivalent antibody titres. Skin
biopsy specimens are the best material from
which to attempt isolation of B. burgdorferi, and
spirochaetes can be isolated from most untreated
patients with early and late skin borreliosis
(EM and ACA, respectively). The success rate
for culture is highest for patients with EM (up to
86%), with biopsy specimens taken close (within
4 mm) to the expanding border of the lesion [96].
Without treatment, B. burgdorferi can persist for
long periods of time in the skin, as shown by
isolation of the organism from a 10-year-old
acrodermatitis lesion [97]. If available, other
biopsy materials from the heart, brain and eye
can be investigated for detection of borreliae.
Ticks are often tested for borreliae as part of
epidemiological studies to assess the risk for
human populations in a given geographical area
(see concluding section of these guidelines).
Diagnostic tools
Serology
Specific antibodies are often not detectable in the
primary stage of the infection with the use of
currently available test methods, but IgG anti-
bodies are frequently present in the second stage
(Table 11). Most cases of neuroborreliosis addi-
tionally show intrathecally produced antibodies
in CSF [98,99]. Patients with stage III illness
typically have high IgG titres, especially if suffer-
ing from arthritis or ACA [100,101]. However, in
late manifestations, IgM can be detected in only
some patients (10–40%, depending on the test
method used) [102]. Intrathecal antibodies are
produced in cases of chronic neuroborreliosis,
and detection of these is the most important
microbiological diagnostic criterion, as direct
detection methods may not succeed and IgM
antibodies are regularly not found.
Although assays allowing detection of a speci-
fic immune response against B. burgdorferi are
used widely, a positive antibody assay in the
absence of the corresponding clinical symptoms is
not sufficient for the diagnosis of Lyme borrelio-
sis. Serological diagnosis can be impaired by
cross-reactivity of borrelial antigens with antigens
of other pathogens, by the delayed appearance, or
even permanent lack, of a measurable immune
response in the early stage of Lyme borreliosis,
and by the absence of a marker of disease activity
in late manifestations.
Many insufficiently evaluated commercial
kits for the detection of antibodies against
B. burgdorferi are currently available, with differ-
ent serological methods and test antigens being
used. These kits have heterogeneous diagnostic
properties that are often unknown to both the
user (laboratory) and the requesting clinician.
Although a complement fixation test is available
commercially, it is not recommended for the diag-
nosis of Lyme borreliosis. The underlying princi-
ple of the complement fixation test suggests that
this method is not sensitive enough to serve as a
screening assay. The indirect immunofluores-
cence antibody assay can also be used for detec-
tion of specific IgG and IgM antibodies. If sera are
preabsorbed with Reiter treponemes, the validity
of the indirect immunofluorescence antibody
assay corresponds to that of a second-generation
assay, as improved specificity is achieved com-
pared with the test with non-absorbed sera.
However, in the early stage of infection, absorp-
tion with Reiter treponemes may in some cases
entail a loss of diagnostic sensitivity. Enzyme
Table 11. Humoral immune response in Lyme disease
[182]
Stages Immune response
I: Early ⁄ localised
infection
Initial IgM response (evolving from approximately
the third week after infection), followed by IgG
antibodies (evolving from approximately the sixth week
after infection). Patients are often seronegative.
IgM antibodies are sometimes undetectable in cases of
short duration
II: Early ⁄disseminated
infection
Immune response similar to stage I, but with
IgG antibodies now predominant. Intrathecal antibody
production in neuroborreliosis
III: Late ⁄persistent
infection
Usually high IgG antibody titres in arthritis and
acrodermatitis. IgM antibodies usually undetectable.
Intrathecal antibody production in chronic
neuroborreliosis
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immunoassay allows differentiation between the
immunoglobulin classes of antibodies. The dis-
tinction between IgM and IgG is of diagnostic
relevance. Commercial tests for the detection of
IgA antibodies are available, but as there are no
convincing data to demonstrate that measure-
ment of this parameter provides clinically rele-
vant information, these assays cannot be
recommended. Overall, second- or third-genera-
tion enzyme immunoassays are more likely to
provide diagnostically useful results than other
serological screening approaches for Lyme dis-
ease.
Western blotting is used currently as a con-
firmatory assay in the serodiagnosis of Lyme
borreliosis, but is usually only employed follow-
ing a positive screening assay. In order to inter-
pret the individual reactivity patterns of patient
sera correctly, it is necessary to be familiar with
the stage-dependent diagnostic significance of
immunogenic proteins. For example, in the diag-
nosis of early Lyme borreliosis, the intensity of at
least some of the immunoblot bands (p41, OspC)
must be taken into account. Therefore, each assay
requires precise internal controls that allow
semi-quantitative evaluation of blot intensities.
Whole-cell antigen assays are available, in which
electrophoretically separated whole-cell lysates
from borreliae are employed, with the borrelial
proteins transferred to blot membranes. Suppliers
also offer recombinant antigen assays in which,
analogously, selected genetically engineered
Borrelia proteins are used. The advantage of
whole-cell lysate Western blots resides in the fact
that a greater number of immunoreactive proteins
can be detected. The main disadvantage is the
difficulty of distinguishing specific from cross-
reactive bands, and examination by an expert is
therefore required. In recombinant Western blots,
specific proteins that can be assigned unambigu-
ously to blot bands are selected. Another advant-
age is that homologous proteins of different
species can be combined [103–105]. Recombinant
blots have long been considered to have poorer
sensitivity than whole-cell lysate blots (provided
that the latter are performed under standardised
conditions with a strain that expresses the diag-
nostically relevant immunodominant proteins).
However, the sensitivity of the recombinant
Western blot has now been improved signifi-
cantly by the addition of recombinant VlsE, a
protein that is primarily expressed only in vivo
[106]. The decisive criterion qualifying the West-
ern blot as a suitable confirmatory assay is thus
reliable identification of the immunoreactive
bands. Numerous tests, using antigens of various
strains or genospecies of B. burgdorferi sl, are
available commercially. In principle, only tests
allowing unequivocal distinction of diagnostically
relevant bands should be used. A further prere-
quisite is reliable specification of these bands by
the manufacturer, i.e., based on their identifica-
tion with monoclonal antibodies (Fig. 6).
There is no single optimum test for the serodi-
agnosis of Lyme borreliosis. The existing methods
must therefore be combined logically in order to
achieve the highest possible diagnostic efficiency.
A stepwise diagnostic protocol is recommended
in which a screening assay, as defined above, is
used as the first step (Fig. 7). If the result of the
screening assay is positive or borderline, a con-
firmatory Western blot should be used. A two-tier
protocol has also been recommended in the USA
Fig. 6.15 Standardisation of immunoblots with reference
sera. G, IgG; M, IgM; 1–11, monoclonal antibodies. The
antigen used was Borellia afzelii (Pko Strain) [92].
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by the Centers for Disease Control (CDC) [107].
Such an approach, the aim of which is to increase
the pre-test probability, and thus the predictive
value, of a positive result with each step, can only
work if the tests are performed in succession.
Following a positive screening assay, the possi-
bility of cross-reactivity with Treponema pallidum
must be considered, and this can be clarified by
means of a T. pallidum haemagglutination assay.
Cultivation
This method should be attempted only in certain
clinical circumstances (Table 10) and should be
carried out by reference laboratories. B. burgdorferi
can be cultivated in an artificial semi-solid
medium [108] (modified Kelly’s medium, e.g.,
MKP medium, described by Preac-Mursic et al.
[109]), but as this approach is time-consuming and
labour-intensive, it is rarely used for the routine
diagnosis of Lyme borreliosis. Attempted isolation
of borreliae is potentially of most diagnostic value
in patients with suggestive clinical presentations,
but no detectable antibody response (seronegative
Lyme borreliosis), e.g., atypical EM, suspected
neuroborreliosis without detection of intrathecal
antibodies, or suspected Lyme borreliosis com-
bined with immune deficiencies. Such seronega-
tive cases are often characterised by a short
duration of disease. Occasionally, culture attempts
may be justified in seropositive patients, e.g.,
patients with dermatological disease manifesta-
tions that cannot be attributed unambiguously to
Lyme borreliosis.
Molecular detection
There are numerous publications on the applica-
tion of PCR-based methods to the diagnosis of
Lyme disease [92,110]. However, neither a stand-
ardised method for DNA isolation nor a routine
PCR method, validated through several clinical-
diagnostic studies and carried out in standardised
conditions, has been established to date. Further-
more, since a negative PCR result cannot be
considered to be indicative of an absence of
borreliae, the use of PCR-based methods alone
cannot currently be recommended for routine
laboratories [92,111]. However, in some circum-
stances, molecular methods can be valuable addi-
tional diagnostic tools, particularly when used in
specialised laboratories with sufficient experience
and the capacity to sequence amplification prod-
ucts.Asmentioned above, no standardisedmethod
for the preparation of DNA templates for diagnos-
tic PCRs has been adopted. Widely different lysis
and DNA extraction techniques have been used in
varying combinations, andno reliable statement on
the quality of the different methods can bemade at
the present time. Therefore, comparison ofmolecu-
lar diagnostic results obtained by different labor-
atories is not yet possible.
In the PCR-based assays described to date, a
variety of different borrelial DNA fragments have
been targeted, including ospA and ospB, genes for
the flagellar protein or p66 (clone 2H1), 16S rRNA
genes, or the 5S ⁄ 23S rRNA intergenic spacer
region. Use of more than one target sequence is
recommended. With the exception of the con-
firmed high detection rates from synovial fluid or
synovial biopsy specimens in Lyme arthritis, the
diagnostic sensitivity of molecular methods is not
significantly greater than that of culture
1ststep*
2ndstep*
In the case of suspected neuroborelliosis: examination of paired serum/CSF samples drawn on
the same day for intrathecally produced antibodies (CSF/serum index) 
Screening assay. IgG-EIA and IgM-EIA
Positive or borderline Negative
NegativePositive
Report as positive 
serological result
Report as equivocal
serological result
Report as negative
serological result
Borderline
No further tests from the present 
serum
In the case of short disease duration 
serological follow-up control
Report as negative serological result
Confirmatory assay: IgG-immunoblot and IgM immunoblot 
If short duration Lyme borelliosis is still suspected clinically:
serological follow-up control
If a long-term course Lyme borelliosis is still suspected 
clinically:
Check special indications for:
(1) serological follow-up control,
(2) use of additional serological methods
(e.g .use of another Borrelia spp. as blotting antigen).
*Screening with a polyvalent assay (e.g. IHA) is possible, followed by Ig class differention:IFA may
also be used as a screenning assay.
Fig. 7.16 Stepwise serodiagnosis of Lyme borelliosis [92].
IFA, immunofluorescent assay; IHA, immunohaemagglu-
tination assay.
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(Table 12). For example, when skin biopsy
specimens and CSF have been used as sources
of template DNA, molecular methods have been
found to have diagnostic sensitivities of 60% and
25%, respectively [93,112].
More information on the microbiological diag-
nosis of Lyme borreliosis can be found in recent
reviews [92,110] or on the internet (http://
www.dghm.org/red/index.html?cname = MIQ,
and alpha1.mpk.med.uni-muenchen.de ⁄ bak ⁄nrz-
borrelia ⁄miqlyme ⁄ Frame-miq-Microbiologi-
cal.html).
Risk assessments
Criteria for the diagnostic assessment of patients
with suspected Lyme borreliosis were published
in 1996 by the European Union Concerted Action
on Lyme Borreliosis (EUCALB) [113] and are
summarised in Table 13.
TULARAEMIA
Organism and vectors
Tularaemia is a zoonotic disease caused by Franci-
sella tularensis, a small, aerobic, pleiomorphic,
catalase-positive, Gram-negative, facultative-
intracellular coccobacillus that grows poorly on
most ordinary culture media [114,115]. There are
three main subspecies or biovars. F. tularensis
subsp. tularensis (or nearctica or biovar A) is the
most virulent species; it is the predominant sub-
species in north America and has been reported
recently from central Europe [116]. F. tularensis
subsp. palaearctica (or holarctica or biovar B) is a less
virulent biovar that occurs in Europe, Asia and
north America, while F. tularensis subsp. novicida
(biovar C) is found in north America and has a low
virulence [115,117]. Tularaemia occurs both spor-
adically and in epidemics, and has been reported
throughout Europe, with the exception of the UK.
The epidemiology of tularaemia is poorly under-
stood, with evidence of infection having been
reported in > 250 animal species, including mam-
mals (particularly hares, rabbits and rodents),
birds, fish, amphibians, arthropods and parasites1
[118]. Multiple routes of transmission have been
reported. The routes of transmission to man
include tick bite (by Dermacentor spp. and Ixodes
spp.), bites of infected mammals, deer flies or
mosquitoes, direct contact with infected animals
(even through intact skin), inhalation [118–120],
ingestion of contaminated water or food [121–124],
and occupational exposure [120,123,125]. Individ-
uals with an increased risk of tularemia are labor-
atory workers, farmers, veterinarians, hunters or
trappers, and cooks or meat handlers [117]. Most
cases are associated with tick exposure and occur
from May to July (65%), whereas those associated
with exposure to animals (rabbits, rodents) occur in
November or December (33%) and from May to
July (22%) [121,125–129].
Clinical and standard laboratory features
The disease varies in severity, depending on the
route of inoculation, the aetiological biovar, the
number of organs involved and the immune
status of the host. The incubation period is
1–21 days (mean, 4–5 days). Classically, tularae-
mia is a severe illness characterised by a sudden
onset of fever, chills, headache, lymphadenopa-
thy, myalgia, malaise and fatigue [117,121,125–
127]. Pulse–temperature dissociation is a classic
finding (42%) [125]. Six classic types of tularaemia
have been described, namely the ulceroglandular
(49–75%) (Fig. 8) [117,121,125–127], glandular
(12.5–15.9%), oculoglandular (0.5–3.5%), oropha-
ryngeal (0–9.2%), typhoidal (8–14%) and pneu-
monic (1.5 to > 50%) forms.
Differential diagnoses are presented in
Table 14. The results of non-specific diagnostic
tests are often unremarkable. The leukocyte count
is usually normal or slightly elevated, and atyp-
ical lymphocytes are sometimes present [130,131].
Serum hepatic aminotransferase levels are often
elevated. Urinary analysis may reveal pyuria in
some (25%) cases [132]. The results of CSF
examination are normal in nearly 70% of cases.
When pathology is present, CSF examination may
reveal an increased number of mononuclear cells,
an elevated protein level, and a decreased glucose
level [125,130,131].
Table 12. Sensitivity of direct pathogen detection methods
for Lyme borreliosis [92]
Specimen Sensitivity
Skin
(erythema migrans, acrodermatitis)
50–70% when using culture or PCR
CSF
(neuroborreliosis, stage II)
10–30% when using culture or PCR
Synovial fluida
(Lyme arthritis)
50–70% when using PCR
(culture is very rarely positive)
aHigher sensitivity in synovial tissue than in synovial fluid.
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Collection and preservation of sample
All samples from patients with suspected tularae-
mia must be processed in Category 3 Safety Level
laboratories. Biopsy specimens of skin lesions
(particularly an inoculation eschar) or lymph node
biopsy specimens, as well as blood (heparin-
containing vial), pharyngeal or sputum samples,
can be used for culture, but must be processed
immediately or stored at ) 80C for culture. Sam-
ples for PCR (with blood obtained on EDTA) may
be maintained at ) 20C. For serological diagnosis,
a blood sample should be collected early in the
course of the disease, and again after 2–4 weeks.
Table 13. Criteria for the diagnosis of Lyme disease based on the EUCALB clinical case definitions for Lyme borreliosis
[113,182]
Disease
Major clinical criteria
(essential)
Minor clinical criteria
(supporting)
Laboratory evidencea
Major criteria
(essential)
Laboratory evidencea
Minor criteria
(supporting)
Erythema
(chronicum)
migrans (EM)
Expanding reddish or
bluish-red patch, often with
central clearing; advancing
edge, typically distinct,
intensely coloured, yet not
markedly elevated; localised
around the point of inoculation
or (rarely) disseminated
Preceding tick bite at
the same localisation
None Detection of B. burgdorferi by
culture or NAT from a skin
biopsy specimen, significant
rise in specific antibodiesb
or detection of specific IgM
Borrelial lymphocytoma
(rare manifestation)
Painless bluish-red nodule or
plaque, usually localised at the
ear lobe, ear helix, nipple or
scrotum, more frequent in
children (especially on ear)
than in adults
EM, present or preceding Detection of serum antibodies
against B. burgdorferi
(IgG and ⁄ or IgM) or significant
rise in the IgG antibody
titre against B. burgdorferi
Histological evidence of
a B-cell pseudolymphocytoma
Acrodermatitis chronica
atrophicans
Long-standing red or bluish-red
lesion, usually on the extensor
surfaces of the extremities. Possible
initial doughy skin swelling,
the lesion becoming eventually
atrophic. Possible skin induration
over bony prominences
High concentration of specific
serum IgG antibodies
or Characteristic histological
evidence for and detection
of B. burgdorferi by culture
or NAT from a skin biopsy
specimen
Early neuroborreliosis Painful meningo-radiculoneuritis
with or without facial palsy or
paresis of other cranial nerves
(Garin–Bujadoux–Bannwarth
syndrome). In children, most
frequently meningitis, isolated
monolateral (occasionally bilateral)
facial palsy or paresis of other
cranial nerves
EM, present or preceding Lymphocytic pleocytosis in CSFc
and Detection of intrathecally
produced specific antibodiesd
or Detection of B. burgdorferi by
culture or NAT from CSF
Specific oligoclonal bands
in CSF; significant rise in specific
serum antibodies
Chronic
neuroborreliosis
(very rare)
Long-standing encephalitis,
meningoencephalitis,
encephalomyelitis,
radiculomyelitis
Detection of intrathecally produced
specific antibodies and
Lymphocytic pleocytosis in CSFc
and Detection of serum antibodies
against B. burgdorferi
Specific oligoclonal bands in CSF
Lyme carditis Acute onset of atrioventricular block
(degrees II and III), rhythm
disturbances, sometimes myocarditis or
or pancarditis (tick exposure is assumed
irrespective of whether or not a tick
bite has occurred)
EM, present or preceding Detection of serum IgG and IgM
antibodies against B. burgdorferi
or Detection of a significant rise
in IgG antibodies against
B. burgdorferi or Detection of
B. burgdorferi by culture
from a heart biopsy specimen
Lyme arthritis 1. Recurrent brief attacks of objective
joint swelling in one or a few large
joints, occasionally progressing to
chronic arthritis and Exclusion of
other causes for the clinical
symptoms
or
2. Recurrent brief attacks of objective
joint swelling in one or a few large
joints, occasionally progressing to
chronic arthritis without history of a
confirmed clinical manifestation of
Lyme disease
1. High concentration of specific
serum serum IgG antibodies
or Only in conjunction with
the clinical major criterion
no. 2
2. High concentration of specific serum
IgG antibodies and Detection of
B. burgdorferi by NAT or
culture from synovial fluid and ⁄ or
synovial fluid biopsy specimen
EM, erythema migrans; NAT, nucleic amplification technique; CSF, cerebrospinal fluid.
aWhen considering the laboratory findings17 , the method-specific indications listed in the text should be observed.
bThe levels of specific serum antibodies may increase as a reaction to disease progress or shortly after the beginning of antibiotic treatment; they may decrease when the
disease is resolved.
cCSF pleocytosis may be absent if only a short time (several days) has elapsed since the onset of the disease, or in children with isolated facial palsy.
dIntrathecally-produced antibodies may not be detectable for a short time after the onset of symptoms.
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Diagnostic tools
Direct examination of sputum is usually not
helpful [125]. A false-positive direct fluorescent
antibody stain for Legionella on a bronchoscopy
specimen has been reported [133]. Pleural fluid,
when present, is serosanguineous, with a pre-
dominance of lymphocytes, and is usually negat-
ive following Gram’s stain. A high pleural fluid
concentration of adenosine deaminase has been
described in a tularaemia pleural effusion [134]. If
a biopsy specimen is taken from a lymph node or
abscess, histopathological examination reveals a
combination of abscess and caseous-type necrosis,
with infiltration of numerous polymorphonuclear
leukocytes [130,135].
Serology
Serology remains the most useful technique for
the diagnosis of tularaemia [136–139]. Various
techniques have been used, including the stand-
ard tube agglutination assay, the microagglutina-
tion test, haemagglutination, immunofluorescence
and ELISA. With the standard tube agglutination
assay, specific antibodies are usually detected
2 weeks after the onset of clinical manifestations,
and reach their maximum titres after 3–4 weeks
[140]. A single antibody titre of ‡ 1:160 is consid-
ered to be significant. Antibodies are usually
detectable within 2 weeks of the onset of symp-
toms, and peak after 4–5 weeks [114]. The micro-
agglutination assay has been reported to be more
sensitive than the standard tube agglutination
assay [136]. The cut-off titres have not been well-
defined with other serological techniques, and
may vary according to geographical region, with
higher cut-off titres being required in endemic
than in non-endemic areas. Since antibodies may
persist for prolonged periods [141], a diagnosis of
tularaemia cannot be established firmly on the
basis of a single serum titre. A four-fold increase
in antibody titre, or a seroconversion between two
sera, with the first being collected at the onset of
Fig. 8. Tularaemia: detail of the neck showing a typical
lymphadenopathy.
Table 14. Differential diagnosis for clinical manifestations
of tularaemia
Manifestation Disease (causative organism if applicable)
Ulceroglandular Anthrax (Bacillus anthracis)
Cat-scratch disease (Bartonella henselae)
Glandular Dermacentor bite rickettsia infection
TIBOLA18 (R. slovaca)
Herpes simplex virus infection
Lymphogranuloma venereum (Chlamydia trachomatis)
Other non-tuberculous mycobacterial infection
Plague (Yersinia pestis)
Pyogenic bacterial infection
Rat-bite fever (Streptobacillus moniliformis, Spirillum minor)
Sporotrichosis (Sporothrix schenckii)
Syphilis (Treponema pallidum)
Toxoplasmosis (Toxoplasma gondii)
Tuberculosis (Mycobacterium tuberculosis)
Oculoglandular Cat-scratch disease (Bartonella henselae)
Herpes simplex virus infection
Pyogenic bacterial infection
Syphilis (Treponema pallidum)
Oropharyngeal Actinomycosis (Actinomyces sp.)
Diphtheria (Corynebacterium diphtheriae)
Extensive necrotic cervical adenopathy
Infectious mononucleosis (Epstein–Barr virus)
Lymphoma
Streptococcal angina (Streptococcus sp.)
Tonsillopharyngitis
Tuberculosis (Mycobacterium tuberculosis)
Typhoidal Acute gastroenteritis
Anthrax (Bacillus anthracis)
Brucellosis (Brucella melitensis)
Endocarditis
Legionnaires’ disease (Legionella pneumophila)
Malaria (Plasmodium sp.)
Q fever (Coxiella burnetii)
Rickettsioses
Typhoid fever (Salmonella typhi)
Pneumonic Anthrax (Bacillus anthracis)
Brucellosis (Brucella melitensis)
Legionnaires’ disease (Legionella pneumophila)
Mycoplasmal pneumonia (Mycoplasma pneumoniae)
Psittacosis (Chlamydia psittaci)
Q fever (Coxiella burnetii)
Tuberculosis (Mycobacterium tuberculosis)
TIBOLA, tick-borne lymphadenopathy.
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clinical manifestations and the second during
convalescence, are much more specific criteria.
Cross-reactions, especially with IgM-type anti-
bodies, have been described between F. tularensis
and Francisella philomiragia [142], Brucella spp.,
Proteus OX19 and Yersinia pestis [114]. Conse-
quently, the specific F. tularensis subspecies of the
infecting organism cannot be determined with
serology.
Cultivation
A diagnosis of tularaemia has rarely been estab-
lished by culture, because isolation of the patho-
gen is both hazardous and insensitive [125].
According to Taylor et al. [143], F. tularensis is
isolated in only c. 10% of cases. Isolation is more
frequent from immunocompromised patients
[144] and from patients with pneumonia (28%)
[145]. F. tularensis is highly infectious by the
aerosol route, and the pathogen should be mani-
pulated in a Biosafety Level 3 laboratory [146].
Vaccination of laboratory personnel working with
F. tularensis has been recommended [147].
F. tularensis is a fastidious bacterium, but
recovery is possible on cystine- or cysteine-
enriched medium after incubation for 2–4 days
at 37C in CO2 5% v ⁄ v. Historically, cystine
glucose blood agar has been the most widely used
medium for isolation of F. tularensis [117]. Growth
may also be obtained on commercially available
chocolate agar supplemented with IsoVitalex
(BBL, Cockeysville, MD, USA) or PolyVitex (bio-
Me´rieux, Marcy l’Etoile, France), as well as in
automated blood culture systems [148–150]. How-
ever, routine blood cultures usually (87.5–95%)
remain sterile [125,145]. Colonies growing on
agar are blue–grey, round, smooth and slightly
mucoid, with a small zone of a-haemolysis on
blood agar. The isolation of F. tularensis with the
use of a cell culture system has recently been
reported [151]. The cell culture system has several
advantages over the axenic medium. It is a more
versatile system, allowing isolation of a number of
strict and facultative intracellular pathogens that
may be responsible for cutaneous lesions and ⁄ or
lymphadenopathy, and it is safer, as vials can be
closed hermetically after inoculation of a clinical
sample.
Molecular detection
Several diferent PCR-based methods have been
applied to the diagnosis of tularaemia [152–154].
Primers have been used that specifically amplify
fragments of a number of genes, including 16S
rDNA [152] and a gene encoding a 17-kDa
lipoprotein [153,154]. These techniques allow the
presence of F. tularensis DNA to be demonstrated
without requiring the hazardous isolation of this
pathogen. However, molecular techniques are
more costly than all of the other diagnostic
techniques available.
Species and subspecies identification
Several biochemical tests have been described
that allow differentiation of F. tularensis subspe-
cies and biovars [117]. An agglutination assay in
which specific sera are used has also been used
for identification of F. tularensis, but does not
allow identification of the biovar [155]. More
accurate differentiation is best achieved with
molecular biological techniques. Forsman et al.
[156,157] and Sandstrom et al. [158] reported
differentiation of F. tularensis subsp. tularensis
from F. tularensis subsp. palearctica on the basis of
16S rDNA sequences. Modern PCR-based epide-
miological methods have been applied success-
fully to the characterisation of F. tularensis strains,
including repetitive extragenic palindromic ele-
ment PCR, enterobacterial repetitive intergenic
consensus sequence PCR and random amplified
polymorphic DNA [159]. More recently, amplifi-
cation of short-sequence tandem repeats has also
been reported [160]. These different approaches
are now facilitated by the sequencing of the entire
F. tularensis subsp. tularensis Schu S4 genome
[161], although recent concerns about the possible
use of F. tularensis for bioterrorist purposes has
resulted in restricted access to the data.
Case definition
Table 15 presents the laboratory criteria defined
by the CDC for the serological diagnosis of
tularaemia [162].
TICK-BORNE RELAPSING FEVER
Organism and vectors
Relapsing fever, an infectious disease with a
sudden onset of high fever with septicaemic signs
and symptoms, is characterised by the occurrence
of one or more spells of fever after the subsidence
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of the primary febrile attack. Tick-borne relapsing
fever (TBRF) is encountered throughout the world
and is caused by at least 16 different Borrelia spp.
that are harboured in soft ticks of the genus
Ornithodoros (Alectorobius). TBRF is a serious dis-
ease with a mortality rate, if untreated, of up to
5%. Each Borrelia sp. associated with relapsing
fever appears to be specific to its tick vector. In
southern Europe, recurrent fever caused by Borre-
lia hispanica has been reported sporadically in the
Iberian Peninsula, Greece and Cyprus [163,164].
The organism is transmitted by Ornithodoros errat-
icus, a species that usually parasitises rodents and
small mammals in their nests. A novel Borrelia sp.
associated with TBRF was isolated and character-
ised in Spain in 1996 [165], while a new species
that is related closely to the TBRF-associated
species Borrelia miyamoto has been detected
recently in Sweden in two of 301 Ixodes ticks
[166]. Many rodents and small mammals serve as
natural reservoirs, and borreliae also persist for
many years in their long-lived tick vectors.
Clinical and standard laboratory features
TBRF is characterised by acute onset of high fever
with chills, headache, myalgia, arthralgia and
coughing [92]. Haemorrhage (rarely severe), iritis
or iridocyclitis, hepatomegaly or splenomegaly
may also occur, and abdominal pain, nausea,
vomiting, diarrhoea and photophobia are common
in African cases. A rashmay occur at the end of the
first febrile episode, and neurological findings are
frequent andmay be severe [92]. Jaundice occurs in
7% of patients, and the case fatality rate is c. 2–5%.
In general, the primary episode lasts about 3 days
and is followed by a second, shorter and milder,
episode after a further 7 days. Thereafter, one or
more subsequent episodes may occur at intervals
of several days, with each episode lasting about
2 days.
Collection and preservation of samples
Blood is the specimen of choice. During febrile
attacks, large numbers of borreliae are detected
easily by dark-field or bright-field microscopy of a
wet-mounted blood sample or a stained blood
smear. The level of spirochetaemia may reach
106–108 cells ⁄mL. Blood from acutely ill patients is
also the best source for confirmation by culture.
However, the spirochetaemia diminishes with
each successive relapse, and visualisation or cul-
ture of borreliae is less successful during afebrile
periods. Serum is suitable for detection of indirect
(antibody) evidence of exposure to borreliae. Spe-
cific antibody detection tests have recently been
employed to confirm cases of relapsing fever.
Diagnostic tools
Examination of blood
Diagnosis is established by the demonstration of
borreliae in the peripheral blood of febrile
patients. This test has a sensitivity of 70% when
blood smears are examined by dark-field micros-
copy or stained with Giemsa or Wright stain.
Recently, a quantitative buffy coat analysis
method has been described as a very sensitive
and specific technique for the detection of borrel-
iae in blood [167].
Serology
Serological assays are not readily available, and
their diagnostic value is limited because of the
antigenic variation shown by the TBRF borreliae
[92].
Cultivation
Borrelia dutonii, the agent causing East African
TBRF, has been propagated successfully in axenic
culture. The spirochaetes are cultivated at 33C on
Table 15. Criteria used by the Centers for Disease Control
for case definition of tularaemia [162]
Clinical description
An illness characterised by several distinct forms, including the following:
Ulceroglandular (cutaneous ulcer with regional lymphadenopathy)
Glandular (regional lymphadenopathy with no ulcer)
Oculoglandular (conjunctivitis with preauricular lymphadenopathy)
Oropharyngeal (stomatitis or pharyngitis or tonsillitis and cervical lymphaden-
opathy)
Intestinal (intestinal pain, vomiting, and diarrhoea)
Pneumonic (primary pleuropulmonary disease)
Typhoidal (febrile illness without early localising signs and symptoms)
Clinical diagnosis is supported by evidence or history of a tick or deer fly bite,
exposure to tissues of a mammalian host of Francisella tularensis, or exposure
to potentially contaminated water.
Laboratory criteria for diagnosis
Presumptive
Elevated serum antibody titre(s) to F. tularensis antigen (without documented
fourfold or greater change) in a patient with no history of tularemia
vaccination or Detection of F. tularensis in a clinical specimen by fluorescent
assay
Confirmatory
Isolation of F. tularensis in a clinical specimen or
Four-fold or greater change in serum antibody titre to F. tularensis antigen
Case classification
Probable
A clinically compatible case with laboratory results indicative of presumptive
infection
Confirmed
A clinically compatible case with confirmatory laboratory results
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BSK II growth medium with added bovine serum
albumin fraction V (Sigma, St Louis, MO, USA)
without antibiotics, and then maintained by serial
passage every 2–3 days [168].
Molecular detection
Nested PCRs targeting fragments of a 16S rRNA-
encoding gene or the flagellin gene have been
described for the detection of TBRF borreliae in
human blood and in ticks [165,166].
TICKS AS TOOLS IN THE DIAGNOSIS
OF TICK-BORNE DISEASES
Ticks themselves can be used as tools for the
diagnosis of tick-borne bacterial disease in
patients. The different steps include the identifi-
cation of the tick(s) to the species level, and the
detection or isolation of infectious disease agents.
This strategy is summarised in Table 16.
Identification of the tick
Ticks can be identified to the family, genus and
species level with use of the numerous taxonomic
keys that are available for ticks from different
regions of the world [2]. However, tick identi-
fication, particularly when larvae are being
studied, can be difficult and may require ento-
mological skills. Molecular methods are currently
being developed to identify ticks, and it is
expected that such methods will be used more
widely in the future, particularly for the differen-
tiation of closely related species [169].
Preservation of the tick
Depending on the studies that are to be per-
formed, ticks can be kept alive in the laboratory at
a relative humidity of 85% and, depending on the
species, at between 15C and 25C. Alternatively,
ticks can be kept at 0–5C in the dark and at 95%
relative humidity for up to 3 months before they
require feeding. However, keeping ticks alive is a
task for specialised laboratories, as their viability
is not necessary for pathogen detection. Indeed,
freezing ticks to ) 80C may be the best storage
option, as this will maintain many infecting
pathogens in a culturable state. Ticks preserved
for long periods of time can still be tested for
pathogens with molecular methods, and these
approaches can also be used on recently dead
ticks, even if they are desiccated or damaged.
Detection of bacteria in ticks
The haemolymph test is performed on live ticks
by amputating the distal portion of a tick leg.
Haemolymph that drains from the amputation
site is smeared onto a microscope slide, stained
and examined for the presence of bacteria. Ticks
from which leg segments have been amputated
can be kept alive and used for subsequent
haemolymph tests or other experiments. Impres-
sion smears may be made of salivary glands or
ovaries removed from dissected ticks, or the
organs may be used for histology. Immunodetec-
tion methods may also be used to detect organ-
isms in haemolymph or organ smears. Slides are
air-dried and fixed in acetone before being treated
with polyclonal or monoclonal antibodies conju-
gated with immunofluorescent labels.
Isolation and cultivation of bacteria from ticks
Currently, rickettsiae are usually isolated with the
use of cell culture systems, with the centrifugation
shell vial technique with HEL fibroblasts being
the method of choice in most reference laborator-
ies. A drop of haemolymph from a surface-
sterilised tick is inoculated on to a confluent
monolayer in the shell vials. Dead ticks may also
be used after surface disinfection. The tick is
macerated in 1 mL of cell culture medium and
then inoculated into shell vials or on the special-
ised BSK II growth medium for borreliae [2].
Molecular detection
Identification strategies based on the DNA
sequences of a number of genes have been des-
cribed for tick-associated bacteria, and also for
Table 16. Strategy for detecting and ⁄or isolating bacteria
from ticks [2]
1. Identification of the ticks to the species level
2. Detection of bacteria in ticks with the use of staining tests (haemolymph for
viable ticks; salivary glands if ticks were frozen), or PCR-based methods
(using one-half of the tick, the other half being kept frozen). PCR may also be
done using only ticks that stain positive
3. Sequencing of the amplified PCR fragment and comparison with sequences
available in sequence databases
4. If there is 100% similarity between the test sequence and the corresponding
sequence of a known organism, the presumptive identification is confirmed
5. If the test sequence appears to be different from all corresponding sequences
available, the organism is probably a new strain and should be isolated and
characterised from the stored frozen part of the tick
1126 Clinical Microbiology and Infection, Volume 10 Number 12, December 2004
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 1108–1132
viruses and parasites. These approaches have been
reviewed in some detail previously [170,171].
CONCLUSIONS
It can be concluded that the aetiological diagnosis
of tick-transmitted diseases is often difficult and
relies on trained personnel in specialised laborat-
ories using very specific tools. Interpretation of
laboratory data is very important in order to
establish the diagnosis. The guidelines described
above are aimed at helping clinicians and micro-
biologists to diagnose infection transmitted by
tick bites and at providing the scientific and
medical community with comprehensive infor-
mation on these infectious diseases.
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